CoChat

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

OBJECTIVE: To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS: Obese subjects (n = 152; age 46 ± 12 years, female 82%, weight 108.6 ± 23.0 kg, BMI 39.6 ± 7.0 kg/m2, IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks. RESULTS: Exenatide-treated subjects lost 5.1 ± 0.5 kg from baseline versus 1.6 ± 0.5 kg with placebo (exenatide − placebo, P < 0.001). Placebo-subtracted difference in percent weight reduction was −3.3 ± 0.5% (P < 0.001). Both groups reduced their daily calorie intake (exenatide, −449 cal; placebo, −387 cal). IGT or IFG normalized at end point in 77 and 56% of exenatide and placebo subjects, respectively. CONCLUSIONS: Exenatide plus lifestyle modification decreased caloric intake and resulted in weight loss in nondiabetic obesity with improved glucose tolerance in subjects with IGT and IFG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1203

Cites

Statistics

Figures

Figure 1 Changes in body weight over 24 weeks in nondiabetic obese subjects treated with lifestyle intervention and randomized to exenatide or placebo. ○, Placebo (n = 78); ▲, exenatide (n = 73). Results derived from mixed-model repeated-measures analysis and presented as least squares means ± SE. Change from baseline: *P < 0.001, †P < 0.05.
Figure 1 Changes in body weight over 24 weeks in nondiabetic obese subjects treated with lifestyle intervention and randomized to exenatide or placebo. ○, Placebo (n = 78); ▲, exenatide (n = 73). Results derived from mixed-model repeated-measures analysis and presented as least squares means ± SE. Change from baseline: *P < 0.001, †P < 0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 16 · Cited by 229

Research works printed but not linked: 1

  1. Lindström, 2003, Lifestyle intervention and 3-year results on diet and physical activity, Diabetes Care, 26, 3230

Metadata

Authors
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M.
Affiliations
  • Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas;
  • Rainier Clinical Research Center (US)
  • Diabetes & Glandular Disease Clinic (US)
  • Eli Lilly (United States) (US)
  • Amylin Pharmaceuticals, San Diego, California.
Corresponding author
Rosenstock, Julio
Venue
Diabetes Care
Published
2010-03-23
Volume
33
Issue
6
Pages
1173-1175
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2107037013
Cited by
229
References
16
Citations by year
2026: 8 · 2025: 14 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 6 · 2020: 6 · 2019: 8 · 2018: 8 · 2017: 16 · 2016: 15 · 2015: 20 · 2014: 19 · 2013: 28 · 2012: 25
FWCI
19.37
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • MannKind Corporation
  • Daiichi-Sankyo
  • Novo Nordisk
  • Johnson and Johnson
  • Fogarty International Center
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
exenatide, GLP-1 receptor agonists, obesity, impaired glucose tolerance, impaired fasting glucose, prediabetes, lifestyle modification, weight loss, glucose tolerance, energy intake
MeSH terms
Exenatide, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Motor Activity, Obesity, Peptides, Prediabetic State, Venoms, Glucose Intolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. https://app.cochat.ai/papers/10.2337/dc09-1203
The paper
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010). Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. Diabetes Care. https://doi.org/10.2337/dc09-1203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.